tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2021 Apr 29.
doi: 10.1111/jdv.17316. Online ahead of print.
Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
El?in Akda?[SUP] 1 [/SUP], Nilsel ?lter[SUP] 1 [/SUP], Bet?l ???t[SUP] 2 [/SUP], ?zlem Erdem[SUP] 2 [/SUP]
Affiliations
Abstract
According to official data published by the World Health Organization, more than 100 million cases worldwide have been confirmed to be infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing over two million deaths. The CoronaVac vaccine, an inactivated vaccine candidate against COVID-19 containing inactivated SARS-CoV-2, is a Chinese vaccine developed by Sinovac Life Sciences.
Keywords: Adverse reaction; COVID-19; CoronaVac vaccination; Pityriasis rosea.
. 2021 Apr 29.
doi: 10.1111/jdv.17316. Online ahead of print.
Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
El?in Akda?[SUP] 1 [/SUP], Nilsel ?lter[SUP] 1 [/SUP], Bet?l ???t[SUP] 2 [/SUP], ?zlem Erdem[SUP] 2 [/SUP]
Affiliations
- PMID: 33914958
- DOI: 10.1111/jdv.17316
Abstract
According to official data published by the World Health Organization, more than 100 million cases worldwide have been confirmed to be infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing over two million deaths. The CoronaVac vaccine, an inactivated vaccine candidate against COVID-19 containing inactivated SARS-CoV-2, is a Chinese vaccine developed by Sinovac Life Sciences.
Keywords: Adverse reaction; COVID-19; CoronaVac vaccination; Pityriasis rosea.